News Highlights


2011 FDA authorized JN's IND for conducting Conjugated Meningococcal vaccine human trials in Hanford, California


2011 Neurology scientists bags Stroke Grant Award - US Govt.


2006-2011 Meningitis vaccine for Disease outbreaks in India & sub-Saharan




Dr.Reddy at Pharma conf-Amsterdam 



Dr. Orten & Dr. Reddy - at CNS World Summit


  Promising New Study Attempts to Perfect a Genital Herpes Vaccine 

Welcome to JN-International Medical Corporation, a U.S. based private  biopharmaceutical corporation, has been developing vaccines for infectious disease and neurological disorders.



Scientific Discovery since 1998 

   Product Exports since 1999






The corporation 

JNI Medical Corp - Admin Building

Do you Know? JN is the 3rd BioPharma, developed patented Meningococcal meningitis serogroups A/C/Y/W135 diphtheria toxoid conjugate vaccine (NmVac-4dt) which is now human phase. JN also developing vaccine for Genital Herpes and therapeutic Ischemic Stroke. Inc5000 Fastest Growing Company



Meningitis outbreaks


Meningococcal meningitis Disease


 Serogroup shift may threatens epidemic and pandemic outbreaks of meningitis JN developing 13 serogroups including Meningitis B combo conjugate vaccine.


Vaccine: NmVac4-ACYW135 DT“NmVac-4dt is among the most complex biotech or biologic products. It’s a combination vaccine that contains four 4 different vaccines in one and can be used with any combination by the geographic prevalence of the disease causing serogroup A, C, Y & W-135”


Neurological THERAPIES
Proof of concept of stroke and neurological diseases


Research JN neurology team has developed Biomarkers and Therapeutics to intervene TIA / Stroke, Epilepsy, Alzheimer's.

  1. Vaccine saves mice

  2. Auto Antibodies NEWS

  3. Biomarkers

  4. Stroke therapeutic



Filled Commitment



JN & Clinton Global


US President Malaria Initiative & JN International Medical Corporation


© 1998-2012 JN-International, Inc. Oakland, Nebraska 68045, USA . BYLAWS TERMS OF USE LEGAL DISCLAIMER